# An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

> **NCT01592786** · PHASE2 · COMPLETED · sponsor: **Forest Laboratories** · enrollment: 906 (actual)

## Conditions studied

- Autism Spectrum Disorder (ASD)
- Autism
- Autistic Disorder
- Asperger's Disorder
- Asperger's
- Pediatric Autism
- Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

## Interventions

- **DRUG:** Memantine Hydrochloride (HCl)

## Key facts

- **NCT ID:** NCT01592786
- **Lead sponsor:** Forest Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2013-07
- **Final completion:** 2013-08
- **Target enrollment:** 906 (ACTUAL)
- **Last updated:** 2014-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01592786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01592786, "An Open-Label Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01592786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*